The International Society for Cell and Gene Therapy (ISCT) has announced the publication in Nature Medicine of a commentary addressing a statement from the US F 12 January 2024
Grifols, the Spanish producer of blood plasma-based products, is not taking the stock market damage done to the company by UK short seller Gotham City Research 11 January 2024
French rare disease company Innate Pharma has received good news from the US Food and Drug Administration, with a partial clinical hold being lifted from its la 5 January 2024
Californian rare disease company Ultragenyx Pharmaceutical (Nasdaq: RARE) has received a positive reimbursement decision from the UK’s health technology assesso 5 January 2024
Johnson & Johnson unit Janssen has presented the first data from the Phase III PERSEUS study at the annual meeting of the American Society of Hematology (ASH). 13 December 2023
Kite, a subsidiary of US biotech major Gilead Sciences, has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in 12 December 2023
At the 65th American Society of Hematology (ASH) annual meeting, Gilead Sciences company Kite has announced results from a three-year follow-up analysis of the 12 December 2023
US pharma major Bristol Myers Squibb has announced the results of two early studies evaluating combinations of CELMoD agent golcadomide in non-Hodgkin lymphomas 12 December 2023
The Johnson & Johnson (NYSE.JNJ) subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting f 11 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.